Working… Menu
Trial record 2 of 12 for:    OPALE

Adult Height Prediction in Congenital Adrenal Hyperplasia (OPALE Model)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03162159
Recruitment Status : Completed
First Posted : May 22, 2017
Last Update Posted : August 11, 2020
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

Congenital Adrenal Hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoïds. The treatment consists in supplementing children with hydrocortisone. Despite care for these children has improved substantially across decades, short adult height (AH) still remains an important consequence of the disease. About 20% of patients have an AH below 2 standard deviations compared to their expected AH.

In the OPALE-Model study, the investigators want to collect data from a cohort of 496 CAH French patients, born between 1970 and 1991 with a known genotype. Using their age, sex, growth, disease, bone maturation and pubertal data, the investigators will build a model which allows to predict their AH using data available at 8 years of age. The growth charts built from this cohort have shown that currently used formula to calculate the predicted AH (Bayley-Pineau's formula) is not applicable to children with CAH.

In this project, the investigators plan to compute an AH prediction model using data from children born between 1970 and 1993, and to validate the model using data from a different cohort (i.e. children born between 1994 and 1998). this choice was due to availability of data for computing the model first, and in a second stage, data from more recently born patients.

Condition or disease Intervention/treatment
Congenital Adrenal Hyperplasia Other: Collection of growth and bone maturation data

Layout table for study information
Study Type : Observational
Actual Enrollment : 496 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: An Adult Height Prediction Model for Congenital Adrenal Hyperplasia From a National Cohort (OPALE Model Study)
Actual Study Start Date : September 2010
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Group/Cohort Intervention/treatment
cohort for model computing
patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
Other: Collection of growth and bone maturation data
cohort for model validation
patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
Other: Collection of growth and bone maturation data

Primary Outcome Measures :
  1. Adult height (AH) [ Time Frame: up to 18 years ]
    AH is defined as i) the height recorded after age 20 in boys or 18 in girls; ii) Or the height recorded when bone age is >= 18 years in boys and 16 years in girls; Or iii) the height measured after growth velocity dropped to <= 1 cm/year.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adullts with Congenital Adrenal Hyperplasia

Inclusion Criteria:

  • children with CAH, genetically proven, classical form, virilizing form, with deficit of 21 hydroxylase, 11 beta hydroxylase, or 3 beta ol dehydrogenase, born between 1972-1993 (cohort 1) and 1994-1998 (cohort 2).
  • medical charts should be available.

Exclusion Criteria:

  • Patients with chronic growth altering disease, Turner syndrome, or other genetic anomaly
  • Patients having received any treatment with Growth Hormone (GH)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03162159

Layout table for location information
Hospices Civils de Lyon
Lyon, France, 69500
Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for investigator information
Study Chair: Catherine Cornu, MD Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon Identifier: NCT03162159    
Other Study ID Numbers: CE-CIC-GREN-09-19
First Posted: May 22, 2017    Key Record Dates
Last Update Posted: August 11, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenal Hyperplasia, Congenital
Adrenogenital Syndrome
Adrenocortical Hyperfunction
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Genetic Diseases, Inborn
Steroid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Gonadal Disorders